Vlad Coric - Oct 3, 2022 Form 4/A - Amendment Insider Report for Biohaven Ltd. (BHVN)

Signature
/s/ George Clark, Attorney-in-Fact
Stock symbol
BHVN
Transactions as of
Oct 3, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
10/12/2022, 06:31 PM
Date Of Original Report
Oct 5, 2022
Previous filing
Sep 28, 2022
Next filing
Oct 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Other $0 0 0% $0.00* 569K Oct 3, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective as of the pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares pursuant to the Separation and Distribution Agreement, dated as of May 9, 2022, by and among RemainCo, the Issuer and Pfizer Inc. ("Pfizer"), each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. (Cont'd in FN2)
F2 (Cont'd from FN1) As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and will subsequently be settled in Common Shares.
F3 This amendment is being filed to correct the amount of shares beneficially owned reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that 105,950 Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares; however, as reflected in this amendment, 52,975 Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. There were no other changes made to the information in the Original Form 4.